Accelerate Diagnostics Reports Second Quarter 2020 Financial Results & Announces New Product Offering
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) reported its Q2 2020 financial results on August 6, showing a 17% increase in net sales to $2.1 million, compared to $1.8 million in Q2 2019. The company ended the quarter with 201 U.S. live revenue-generating instruments and an additional 213 contracted but not live instruments. However, the net loss stood at $19.2 million, or $0.35 per share. The gross margin decreased to 45% from 50% due to lower overhead absorption. The company launched the PhenoAST Test and plans to launch the PhenoPrep instrument in Q1 2021, bolstering its product portfolio amidst pandemic-related challenges.
- Net sales increased by 17% to $2.1 million compared to Q2 2019.
- Launched the PhenoAST Test and announced the upcoming PhenoPrep instrument.
- Entered an exclusive agreement with Ascend Diagnostics to commercialize a desktop MALDI system.
- Year-to-date net sales are up 22% compared to the same period last year.
- Net loss of $19.2 million for Q2 2020, including $3.4 million in non-cash stock-based compensation.
- Gross margin decreased to 45% from 50% due to lower absorption of labor and overhead costs.
- Total cash used in Q2 was $8.1 million, with a net cash use of $24.5 million year-to-date.
TUCSON, Ariz., Aug. 6, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2020.
"While the progress of new contracts and go-lives continued to be slowed by the effects of the pandemic, utilization within our existing base of live Pheno instruments continued to prove durable during the second quarter," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc. "Despite these external disruptions, our internal R&D teams have made considerable progress, enabling today's announcement of several new products as part of our enhanced portfolio strategy. These include the immediate launch of an AST-only test kit and the imminent launch of a new workflow instrument, the PhenoPrep, the first application of which is enabling automated rapid MALDI identification results. We also entered into an exclusive supply and collaboration arrangement with Ascend Diagnostics to commercialize a complementary desktop MALDI instrument. We are excited about these new additions to our product portfolio and believe they will help position Accelerate for sustained success and more rapid adoption of our technology as the market continues to recover from the unprecedented impacts of COVID-19."
Second Quarter 2020 Highlights
- Added 6 new contracted instruments in the quarter and brought 6 instruments live, including 4 in the U.S.
- Ended the second quarter with 201 U.S. live revenue-generating instruments, with another 213 U.S. contracted Pheno instruments not yet live.
- Net sales of
$2.1 million , compared to$1.8 million in the second quarter of 2019, or17% growth. - Gross margin was
45.0% for the quarter, compared to50% in the second quarter of 2019. This decrease was the result of lower absorption of labor and overhead costs in the current quarter. - Selling, general, and administrative expenses for the quarter were
$11.3 million , compared to$12.8 million in the second quarter of 2019. This decrease was driven by pandemic-related reductions in sales and marketing spend related to travel and trade shows. - Research and development (R&D) costs for the quarter were
$5.3 million , compared to$6.1 million in the second quarter of 2019. This decrease was the result of increased efficiencies and lower external study spend. - Net loss was
$19.2 million in the second quarter, or$0.35 per share, which included$3.4 million in non-cash stock-based compensation expense. - Net cash used in the quarter was
$8.1 million , and the company ended the quarter with total cash, investments, and cash equivalents of$88.7 million . - Launched PhenoAST Test, an AST-only test kit, and announced the upcoming launch of PhenoPrep instrument in Q1 2021
- Entered into exclusive supply and collaboration agreement with Ascend Diagnostics to commercialize a desktop MALDI system.
- Recently submitted final FDA Emergency Use Authorization review items and data for the MS Fast fully-automated chemiluminescence immunoassay analyzer and SARS-CoV-2 tests for the detection of IgG and IgM.
Year to Date 2020 Highlights
- Net sales were
$4.4 million year-to-date as compared to$3.6 million from the same period in the prior year, or22% growth. - Gross margin was
45.0% year-to-date, compared to49% from the same period in the prior year. This decrease was the result of lower absorption of labor and overhead costs in the first half of 2020. - Selling, general, and administrative expenses were
$24.3 million year-to-date, compared to$25.6 million from the same period in the prior year. This decrease was driven by pandemic-related reductions in sales and marketing spend related to travel and trade shows. - Research and development (R&D) costs were
$11.2 million year-to-date, compared to$13.1 million from the same period in the prior year. This decrease was the result of increased efficiencies and lower external study spend. - Net loss was
$40.5 million year-to-date, or$0.74 per share, which included$7.6 million in non-cash stock-based compensation expense. - Net cash used was
$24.5 million year-to-date, and the company ended the quarter with total cash, investments, and cash equivalents of$88.7 million .
Full financial results for the quarter ending June 30, 2020 will be filed on Form 10-Q through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov.
Audio Webcast and Conference Call
The company will host a conference call at 4:30PM ET today to review its second quarter results. To participate in the conference call, dial +1.877.883.0383 and enter the conference ID: 6487727. International participants may dial +1.412.902.6506. Please dial in 10 to 15 minutes prior to the start of the conference call. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using replay code 10145894 until August 27, 2020.
This conference call will also be webcast and can be accessed from the "Investors" section of the company's website at axdx.com/investors. A replay of the audio webcast will be available until November 7, 2020.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and technology, or recent publications, visit axdx.com.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as, among others, Mr. Phillips statements about adapting our business to maximize our commercial execution in the near term and our longer-term initiative to strengthen our commercial foundation and expand our portfolio of products. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 27, 2020, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEET (in thousands, except share data) | ||||||
June 30, | December 31, | |||||
2020 | 2019 | |||||
Unaudited | ||||||
ASSETS | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ | 47,368 | $ | 61,014 | ||
Investments | 41,326 | 47,437 | ||||
Trade accounts receivable | 2,592 | 3,222 | ||||
Inventory | 8,723 | 8,059 | ||||
Prepaid expenses | 1,400 | 955 | ||||
Other current assets | 1,099 | 1,165 | ||||
Total current assets | 102,508 | 121,852 | ||||
Property and equipment, net | 8,004 | 7,905 | ||||
Right of use assets | 3,569 | 3,917 | ||||
Other non-current assets | 734 | 750 | ||||
Total assets | $ | 114,815 | $ | 134,424 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Current liabilities: | ||||||
Accounts payable | $ | 2,702 | $ | 2,351 | ||
Accrued liabilities | 3,346 | 3,828 | ||||
Accrued interest | 1,262 | 1,262 | ||||
Deferred revenue | 232 | 271 | ||||
Current portion of long-term debt | 2,129 | — | ||||
Current operating lease liability | 447 | 450 | ||||
Total current liabilities | 10,118 | 8,162 | ||||
Non-current operating lease liability | 3,366 | 3,579 | ||||
Other non-current liabilities | 190 | 19 | ||||
Long-term debt | 2,662 | — | ||||
Convertible notes | 135,469 | 130,043 | ||||
Total liabilities | $ | 151,805 | $ | 141,803 | ||
Commitments and contingencies | ||||||
Stockholders' deficit: | ||||||
Preferred shares, | ||||||
5,000,000 preferred shares authorized and none outstanding as of June 30, 2020 and December 31, 2019 | — | — | ||||
Common stock, | ||||||
85,000,000 common shares authorized with 56,249,482 shares issued and outstanding on June 30, 2020 and 85,000,000 common shares authorized with 54,708,792 shares issued and outstanding on December 31, 2019 | 56 | 55 | ||||
Contributed capital | 463,178 | 452,344 | ||||
Treasury stock | (45,067) | (45,067) | ||||
Accumulated deficit | (455,297) | (414,653) | ||||
Accumulated other comprehensive income (loss) | 140 | (58) | ||||
Total stockholders' deficit | (36,990) | (7,379) | ||||
Total liabilities and stockholders' deficit | $ | 114,815 | $ | 134,424 | ||
See accompanying notes to condensed consolidated financial statements. | ||||||
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Unaudited (in thousands, except per share data) | |||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||
June 30, | June 30, | June 30, | June 30, | ||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||
Net sales | $ | 2,125 | $ | 1,806 | $ | 4,468 | $ | 3,557 | |||||
Cost of sales | 1,171 | 907 | 2,459 | 1,823 | |||||||||
Gross profit | 954 | 899 | 2,009 | 1,734 | |||||||||
Costs and expenses: | |||||||||||||
Research and development | 5,347 | 6,149 | 11,189 | 13,083 | |||||||||
Sales, general and administrative | 11,332 | 12,837 | 24,275 | 25,559 | |||||||||
Total costs and expenses | 16,679 | 18,986 | 35,464 | 38,642 | |||||||||
Loss from operations | (15,725) | (18,087) | (33,455) | (36,908) | |||||||||
Other income (expense): | |||||||||||||
Interest expense | (3,835) | (3,528) | (7,584) | (6,987) | |||||||||
Foreign currency exchange gain (loss) | 91 | 6 | (37) | (53) | |||||||||
Interest income | 224 | 812 | 604 | 1,653 | |||||||||
Other income (expense), net | 15 | (1) | (67) | (3) | |||||||||
Total other expense, net | (3,505) | (2,711) | (7,084) | (5,390) | |||||||||
Net loss before income taxes | (19,230) | (20,798) | (40,539) | (42,298) | |||||||||
Provision for income taxes | — | (17) | — | (238) | |||||||||
Net loss | $ | (19,230) | $ | (20,815) | $ | (40,539) | $ | (42,536) | |||||
Basic and diluted net loss per share | $ | (0.35) | $ | (0.38) | $ | (0.74) | $ | (0.78) | |||||
Weighted average shares outstanding | 55,445 | 54,476 | 55,139 | 54,407 | |||||||||
Other comprehensive loss: | |||||||||||||
Net loss | $ | (19,230) | $ | (20,815) | $ | (40,539) | $ | (42,536) | |||||
Net unrealized gain (loss) on debt securities available-for-sale | (44) | 98 | 179 | 219 | |||||||||
Foreign currency translation adjustment | 34 | 50 | 19 | (26) | |||||||||
Comprehensive loss | $ | (19,240) | $ | (20,667) | $ | (40,341) | $ | (42,343) | |||||
See accompanying notes to condensed consolidated financial statements. | |||||||||||||
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Unaudited (in thousands) | ||||||
Six Months Ended | ||||||
June 30, | June 30, | |||||
2020 | 2019 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (40,539) | $ | (42,536) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | 1,571 | 1,236 | ||||
Amortization of investment discount | 13 | (320) | ||||
Equity-based compensation | 7,615 | 6,278 | ||||
Amortization of debt discount and issuance costs | 5,426 | 4,843 | ||||
Realized loss on sale of investments | 3 | — | ||||
Loss on disposal of property and equipment | 527 | 407 | ||||
Contributions to deferred compensation plan | (160) | — | ||||
(Increase) decrease in assets: | ||||||
Accounts receivable | 550 | (51) | ||||
Inventory | (1,979) | (2,217) | ||||
Prepaid expense and other | (363) | (588) | ||||
Increase (decrease) in liabilities: | ||||||
Accounts payable | 390 | 476 | ||||
Accrued liabilities, and other | (581) | (1,110) | ||||
Deferred revenue and income | (39) | 38 | ||||
Deferred compensation | 171 | (18) | ||||
Net cash used in operating activities | (27,395) | (33,562) | ||||
Cash flows from investing activities: | ||||||
Purchases of equipment | (643) | (76) | ||||
Purchase of marketable securities | (21,509) | (17,601) | ||||
Proceeds from sales of marketable securities | — | 13,400 | ||||
Maturities of marketable securities | 27,844 | 54,447 | ||||
Net cash provided by investing activities | 5,692 | 50,170 | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of common stock | 216 | 251 | ||||
Proceeds from exercise of options | 3,031 | 4,369 | ||||
Proceeds from debt | 4,791 | — | ||||
Net cash provided by financing activities | 8,038 | 4,620 | ||||
Effect of exchange rate on cash | 19 | (19) | ||||
(Decrease) increase in cash and cash equivalents | (13,646) | 21,209 | ||||
Cash and cash equivalents, beginning of period | 61,014 | 66,260 | ||||
Cash and cash equivalents, end of period | $ | 47,368 | $ | 87,469 | ||
See accompanying notes to condensed consolidated financial statements. | ||||||
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) Unaudited (in thousands) | ||||||
Six Months Ended | ||||||
June 30, | June 30, | |||||
2020 | 2019 | |||||
Non-cash investing activities: | ||||||
Transfer of instruments from inventory to property and equipment | $ | 1,288 | $ | 1,715 | ||
Supplemental cash flow information: | ||||||
Interest paid | $ | 2,144 | $ | 2,144 | ||
Income taxes paid, net of refunds | $ | 26 | $ | 9 | ||
See accompanying notes to condensed consolidated financial statements. | ||||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-reports-second-quarter-2020-financial-results--announces-new-product-offering-301107931.html
SOURCE Accelerate Diagnostics, Inc.
FAQ
What are the financial results for AXDX in Q2 2020?
What is the net loss for AXDX in 2020?
How did the pandemic affect AXDX's operations?
What new products did AXDX launch recently?
